{
    "info": {
        "nct_id": "NCT04431791",
        "official_title": "A Single-center，Observational，Ambispective Cohort Study of Regorafenib Versus Fruquintinib in Metastatic Colorectal Cancer Patients Who Have Progressed After at Least Second Lines of Chemotherapies",
        "inclusion_criteria": "1. signed and dated informed consent.\n2. Diagnosis of histologically confirmed colorectal cancer, stage IV.\n3. after second-line therapy.\n4. gastrointestinal physician prescribed to receive regorafenib or fruquintinib according the patients' condition.",
        "exclusion_criteria": "1. received regorafenib or fruquintinib before third-line therapy.\n2. the clinicopathological characteristics and previous therapy were unknown.\n3. regorafenib or fruquintinib treatment is less than one cycle in the historical cohort.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. signed and dated informed consent.",
            "criterions": [
                {
                    "exact_snippets": "signed and dated informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Diagnosis of histologically confirmed colorectal cancer, stage IV.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of histologically confirmed colorectal cancer",
                    "criterion": "colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "stage IV",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. after second-line therapy.",
            "criterions": [
                {
                    "exact_snippets": "after second-line therapy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "after second-line"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. gastrointestinal physician prescribed to receive regorafenib or fruquintinib according the patients' condition.",
            "criterions": [
                {
                    "exact_snippets": "gastrointestinal physician prescribed",
                    "criterion": "gastrointestinal physician prescription",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receive regorafenib or fruquintinib",
                    "criterion": "medication",
                    "requirements": [
                        {
                            "requirement_type": "options",
                            "expected_value": [
                                "regorafenib",
                                "fruquintinib"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "according the patients' condition",
                    "criterion": "patients' condition",
                    "requirements": [
                        {
                            "requirement_type": "consideration",
                            "expected_value": "condition-based"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. received regorafenib or fruquintinib before third-line therapy.",
            "criterions": [
                {
                    "exact_snippets": "received regorafenib",
                    "criterion": "regorafenib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received ... fruquintinib",
                    "criterion": "fruquintinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. the clinicopathological characteristics and previous therapy were unknown.",
            "criterions": [
                {
                    "exact_snippets": "clinicopathological characteristics",
                    "criterion": "clinicopathological characteristics",
                    "requirements": [
                        {
                            "requirement_type": "knowledge",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "previous therapy",
                    "criterion": "previous therapy",
                    "requirements": [
                        {
                            "requirement_type": "knowledge",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. regorafenib or fruquintinib treatment is less than one cycle in the historical cohort.",
            "criterions": [
                {
                    "exact_snippets": "regorafenib or fruquintinib treatment is less than one cycle",
                    "criterion": "regorafenib or fruquintinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "cycle"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}